The Integration of Diabetic Eye Screening into Hemodialysis Units in Northern Ireland
- PMID: 36245648
- PMCID: PMC9528388
- DOI: 10.34067/KID.0001802022
The Integration of Diabetic Eye Screening into Hemodialysis Units in Northern Ireland
Abstract
Background: Diabetes is rising globally and is the most common cause of both end-stage renal disease and blindness. People on hemodialysis have to attend several dialysis appointments per week, which can affect their attendance at diabetic eye screening. In addition, previous literature suggests patients on hemodialysis are more likely to have sight-threatening diabetic eye disease. This study aims to determine attendance at the Diabetic Eye Screening Program in Northern Ireland, diabetic retinopathy severity, and use of handheld retinal imaging in people with diabetes attending hemodialysis units in Northern Ireland.
Methods: All patients with diabetes attending hemodialysis clinics regionally were screened and graded by the Diabetic Eye Screening Program in Northern Ireland using a handheld and/or conventional nonmydriatic fundus camera.
Results: All eligible people (N=149) were offered a Diabetic Eye Screening Program in Northern Ireland appointment, 132 attended, 34% of whom had not been seen in >3 years and 15% of whom had never attended the Diabetic Eye Screening Program in Northern Ireland despite multiple previous appointments. Altogether, 13% required urgent referral to hospital eye services, which is significantly higher than the national average of 0.4%.
Conclusions: Those on hemodialysis are at high risk for sight-threatening diabetic retinopathy. Implementing the Diabetic Eye Screening Program in Northern Ireland in hemodialysis clinics enables timely diagnosis and referral.
Keywords: Northern Ireland; diabetes; diabetes and the kidney; diabetic eye disease; diabetic retinopathy; eye screening; hemodialysis; nephrology.
Copyright © 2022 by the American Society of Nephrology.
Conflict of interest statement
T. Peto reports research funding for Boehringen Ingelheim, Novartis, and Roche; an advisory or leadership role for Alimera, Apellis, Bayer, Novartis, Oxurion, and Roche; and participation in a speakers’ bureau for Alimera, Apellis, Bayer, Novartis, Oxurion, and Roche (speaker). All remaining authors have nothing to disclose.
Comment in
-
Seeing the Light: Improving Diabetic Retinopathy Outcomes by Bringing Screening to the Dialysis Clinic.Kidney360. 2022 Sep 29;3(9):1474-1476. doi: 10.34067/KID.0003752022. eCollection 2022 Sep 29. Kidney360. 2022. PMID: 36245657 Free PMC article. No abstract available.
References
-
- Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J; Emerging Risk Factors Collaboration : Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies [published correction appears in Lancet 376: 958, 2010 10.1016/S0140-6736(10)61452-3]. Lancet 375: 2215–2222, 2010. 10.1016/S0140-6736(10)60484-9 - DOI - PMC - PubMed
-
- UK Renal Registry : UK Renal Registry 23rd annual report—Data to 31/12/2019. Bristol, United Kingdom: UK Renal Registry, 2021
MeSH terms
LinkOut - more resources
Full Text Sources
Medical